We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Eli Lilly shares climbed to a record high following a stronger-than-expected earnings report fueled by surging demand for weight-loss and diabetes treatments Zepbound and Mounjaro. The company lifted its full-year revenue outlook due to robust weight-loss drug sales, though it trimmed its profit view to account for deal charges. Strong GLP-1 drug performance also drove another guidance lift as the obesity-drug boom continued to expand across the market. Meanwhile, ServiceNow stock experienced a sharp plunge during the same earnings update cycle.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Eli Lilly stock hit a record high after the company reported stronger-than-expected earnings driven by weight-loss drugs Mounjaro and Zepbound.
- ✓ The company lifted its revenue outlook based on weight-loss drug sales while trimming its profit view on deal charges.
- ✓ Sales of obesity drug Zepbound and diabetes treatment Mounjaro surged in the third quarter.
What changed
Eli Lilly raised its annual revenue outlook following third-quarter results driven by weight-loss drug sales.
Live updates
-
Eli Lilly Raises Outlook As GLP-1 Demand Drives Stock Surge
Eli Lilly shares climbed to a record high following a stronger-than-expected earnings report fueled by surging demand for weight-loss and diabetes treatments Zepbound and Mounjaro. The company lifted its full-year revenue outlook due to robust weight-loss drug sales, though it trimmed its profit view to account for deal charges. Strong GLP-1 drug performance also drove another guidance lift as the obesity-drug boom continued to expand across the market. Meanwhile, ServiceNow stock experienced a sharp plunge during the same earnings update cycle.
Why it matters
The pharmaceutical giant benefited from robust uptake of its flagship metabolic treatments, which have become primary drivers of market capitalization growth reaching 1.2 trillion dollars. Wall Street analysts responded to the sustained demand surge by adjusting price targets upward. The ongoing expansion highlights how pharmaceutical firms rely heavily on metabolic and obesity pipelines for major financial gains.
What is confirmed
- Eli Lilly stock hit a record high after the company reported stronger-than-expected earnings driven by weight-loss drugs Mounjaro and Zepbound.
- The company lifted its revenue outlook based on weight-loss drug sales while trimming its profit view on deal charges.
- Sales of obesity drug Zepbound and diabetes treatment Mounjaro surged in the third quarter.
Still unconfirmed
- ServiceNow stock plunged during the earnings updates.
What to watch next
- Execution on the next growth engine identified by the finance chief
- Performance of Mounjaro and Zepbound sales in upcoming quarters
confidence 95%Sources used for this update (8)
- Reuters — Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
- Yahoo Finance — Earnings live updates: Eli Lilly stock pops as strong GLP-1 drug demand lifts results, ServiceNow stock plunges
- CNBC — We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- Fierce Pharma — Lilly breaks down Medicare Bridge boon as GLP-1 sales drive another guidance lift
- Barron's — Eli Lilly Stock Jumps on Monster Earnings as Finance Chief Eyes Next Growth Engine
- www.cnbc.com — Eli Lilly (LLY) earnings Q3 2026 - CNBC
- www.cnbc.com — We're raising our Eli Lilly price target as obesity-drug boom ...
- nypost.com — Demand for weight-loss drugs fuels Eli Lilly stock surge ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community